公开(公告)号：US20120301544A1

公开(公告)日：2012-11-29

申请号：US13574189

申请日：2011-01-18

Applicant: Beth Okutan ,  Peter Draper ,  James Draper

Inventor： Beth Okutan ,  Peter Draper ,  James Draper

IPC: A61K9/48 ,  A61K31/4545

Abstract: This invention relates to a loratadine formulation suitable for encapsulation into a soft gel capsule or suitable dosage unit improved functionality providing enhanced in vitro dissolution and bioavailability of loratadine. The invention also provides a formulation with improved functionality as a highly concentrated solution within a given fill volume in order to manufacture as small a capsule as possible to facilitate consumer acceptance and acceptable manufacturing costs. The invention also relates to a formulation of optimal stability for supporting fill composition compatible with the soft gel capsule dosage unit.

Abstract translation: 本发明涉及适用于包封在软胶囊中的氯雷他定制剂或合适的剂量单位，其改进的功能性提供了氯雷他定的增强的体外溶出度和生物利用度。 本发明还提供了一种在给定填充体积内作为高度浓缩的溶液具有改进的功能的制剂，以便制造尽可能小的胶囊以便于消费者接受和可接受的制造成本。 本发明还涉及用于支持与软凝胶胶囊剂量单元相容的填充组合物的最佳稳定性的配方。